Acute myeloid leukemia

Results with clinical significance

The presence and pattern of gene mutations in a known or suspected hematologic neoplasm can provide critical diagnostic, prognostic, and therapeutic information for physicians. While many hematologic neoplasms show morphologic or phenotypic similarities, most harbor a distinct composition of somatic gene mutations. In addition, many myeloid neoplasms lack a clonal bone marrow cytogenetic finding at diagnosis (normal karyotype) but can be better characterized with the aid of a sufficiently comprehensive gene mutation profile.

Test menu

FISH testing

MRD testing

NGS testing

At Mayo Clinic Laboratories, we strive to provide the highest quality molecular services available to complement your clinical practice by offering a robust menu of clinically validated testing, including:

  • Genetic testing panels, including MayoComplete Next-Generation Sequencing testing: a comprehensive, 47-gene Myeloid Neoplasms OncoHeme panel and two acute myeloid leukemia (AML)-focused subpanels.
  • A comprehensive, disease-specific menu of fluorescence in situ hybridization (FISH) panels.
  • Molecular analysis that combines reverse transcription, real-time polymerase chain reaction (RT-PCR) technology, and DNA-based fragment analysis to evaluate measurable residual disease (MRD).

Cost-savings comparison for traditional myelodysplastic syndromes (MDS) ordering:

  • Historical ordering pattern — chromosomes and MDS FISH ordered in tandem.
  • Research has shown FISH is not needed when chromosome results are successful.
  • Mayo Clinic algorithm to hold FISH and cancel when chromosome results are successful.
  • 70% reduction in unnecessary FISH testing.
  • 100 MDS patients = average savings of $49,000.

Learn more about our AML testing algorithms.

Download now

Learn more about how to order these evaluations at your institution.